AblePay raises $20M to expand a decade-old patient-payment business

Why it matters

AblePay is raising growth capital for a decade-old model that shifts patient-bill collection risk away from health systems. Its reported provider reach offers some evidence of distribution, but the company has not disclosed current enrollment or payment volume, the metrics needed to judge adoption and the business's economics.

AblePay Health, the Allentown patient-payment company founded by John Fistner, raised a $20 million Series A on October 7th. F-Prime led the round, with participation from A1 Health Ventures and .406 Ventures. Founder and CEO Fistner said AblePay will use the capital to grow, develop its technology and reach more health systems and patients, according to AblePay's announcement.

Fistner started AblePay in 2016 after working in hospital operations. His SXSW contributor biography says he served as CFO, COO and partner in a hospital network. It lists JDR Consulting, founded in 2012, and FM Cost Containment, founded and funded in 2014; Fistner exited FM Cost Containment in 2018. The biography does not say he exited JDR Consulting. It traces AblePay's founding thesis to rising deductibles and coinsurance, which were creating financial pressure for patients, employers and providers.

How AblePay handles the bill

AblePay describes its program as a secondary payer that works alongside a patient's primary health insurance. Patients enroll for free, choose payment terms and may receive savings of up to 13% on eligible out-of-pocket bills. AblePay says patients can also get help from its billing advocacy team. For participating providers, AblePay says it assumes collection risk and pays the contracted amount within 14 business days of a claim, according to its provider materials. A 2025 release to the Montana Hospital Association says payment terms can extend up to 24 months; the savings and terms are company-stated features, not independently audited results.

The arrangement puts AblePay between patients and providers after insurance determines the patient's share. A health system gets a faster, more predictable payment and transfers collection work and risk to AblePay. Patients get payment options and potential discounts, with AblePay handling billing questions. Those economics depend on provider participation and patients using the program, yet the financing announcement provides no current enrollment, payment-volume or provider-count figures.

AblePay has offered some evidence of reach, with an important qualifier. A 2025 Montana Hospital Association release carrying company-provided background says AblePay served health systems, hospitals and providers in 28 states and had endorsements from 21 state hospital associations. The figures are AblePay-reported, not independently verified market totals. A 2020 Lehigh Valley profile reported more than 20,000 members at that time; it is a historical snapshot, not a current enrollment count.

AblePay operates in a broader market for medical-bill payment and financing. PayZen markets structured payment plans, while PayMedix reported more than $7 billion in processed medical payments when it announced a $33 million equity-and-debt financing in January 2026. AblePay's stated model combines patient savings and advocacy with non-recourse provider payments. The available figures do not establish how its pricing, approval rates or provider retention compare with those of competitors.

The investor mix includes a potential route into health systems, though no customer commitments were announced. A1 says its limited partners operate more than 110 hospitals and serve more than 15 million patients; the financing release does not say those institutions will adopt AblePay. Fistner's provider-side experience helps explain the product's focus on collections, while AblePay continues to sell a program aimed at both the patient balance and the provider's revenue cycle.

The filing puts a finer point on the round

A Form D filed with the Securities and Exchange Commission on September 16th reports $20,164,890 sold to five investors, with the first sale dated August 28th. That is $164,890 above the announced $20 million. The filing identifies Fistner and F-Prime principal Nikhil Marathe as managers or directors associated with the issuer, but does not name the five investors. AblePay's release names F-Prime, A1 Health Ventures and .406 Ventures as participants.

The filing also records $829,926 in sales commissions. It does not explain the difference between the amount sold and the rounded announcement figure. AblePay has disclosed no valuation or current operating metrics such as revenue, patient enrollment or payment volume, leaving investors without those measures of the business's scale or the price they paid.

AblePay's announcement cited Centers for Medicare & Medicaid Services data showing $591 billion in U.S. out-of-pocket healthcare spending in 2025, up 6% year over year. That spending figure does not establish AblePay's addressable share or how much of it runs through the platform. AblePay is using this financing to extend a model it has operated for about a decade; the public information available with the announcement leaves adoption and payment volume unanswered.